Skip to main content

Advertisement

Table 4 Base case results

From: Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Overview of base case results comparing SLIT allergen and SCIT allergoid immunotherapy
Discounted and undiscounted total QALYs per treatment after a time horizon of 9 years
  Discounted Undiscounted     
5-grass tablet 7.316 8.207     
Allergoid mix 7.280 8.166     
Symptomatic tx 7.235 8.116     
Absolute and relative distribution of total undiscounted costs over individual cost components after 9 years
  5-grass tablet Allergoid mix Symptomatic
  Cost Perc. Cost Perc. Cost Perc.
Visits (e.g. Dermatologist) € 267 15.0% € 299 22.9% € 227 62.4%
Injection/control € 4 0.2% € 69 5.2% € 0 0.0%
Diagnostics € 21 1.2% € 21 1.6% € 0 0.0%
Treatment costs € 1,381 77.7% € 809 61.8% € 0 0.0%
Other drugs costs € 82 4.6% € 86 6.6% € 102 28.1%
Asthma € 23 1.3% € 25 1.9% € 34 9.5%
Total € 1,778 100% € 1,308 100% € 363 100.0%
Discounted and undiscounted total costs per treatment and incremental costs after a time horizon of 9 years
  Discounted Undiscounted   
  Total Inc. vs. 5-grass tablet Total Inc. vs. 5-grass tablet   
5-grass tablet € 1,707   € 1,778    
Allergoid mix € 1,249 € 458 € 1,308 € 470   
Symptomatic tx € 322 € 1,385 € 363 € 1,415   
Discounted and undiscounted incremental costs and ICERs after a time horizon of 9 years
  Inc. Costs Inc. QALYs ICER    
Discounted       
5-grass tablet vs. Allergoid mix € 458 0.036 € 12,593    
5-grass tablet vs. Symptomatic tx € 1,385 0.081 € 17,007    
Undiscounted       
5-grass tablet vs. Allergoid mix € 470 0.041 € 11,576    
5-grass tablet vs. Symptomatic tx € 1,415 0.090 € 15,635